pubrio
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

Public
alnylam.com
バイオテクノロジー研究2,600+ employeesFounded 2002🇺🇸 アメリカ合衆国

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

設立年
2002
従業員数
2,600+
業種
バイオテクノロジー研究
企業タイプ
Public Company
株式
nasdaq: ALNY
本社
🇺🇸Cambridge, Massachusetts (+8)
専門分野
リサーチ製薬バイオテクノロジー医療バイオテクノロジー研究
5 / 11
アクティブな市場
イギリス · ドイツ · スイス
2
新規市場
フランス · インド
信頼度
ほとんどが初期シグナル
0%
モメンタム
前期比
33 / 100
拡大スコア
発展中
ステージ1検討中10投資中
6 件のシグナル · 過去 90 日間

グローバル展開

ライブ
イギリスドイツスイス
ステージ
検討中投資中参入中稼働中
+8さらに市場ロック中
11件中3件を表示

市場タイムラインとシグナルフィードを解放

アクティビティパルス

過去 90 日間に 6 件のシグナル。

過去 90 日間
採用
6↑ +100%
採用
マーケティング・PR
0
アクティビティなし
プロダクト・技術
0
アクティビティなし
+2さらにカテゴリロック中
5件中3件を表示

市場参入タイムライン

この企業が各市場へ参入した順序 — 古い順から新しい順へ

1
🇬🇧イギリス1st 番目に参入した市場 · 2022進行中
投資中
24 件のシグナル投資中 ステージ
2
🇩🇪ドイツ2nd 番目に参入した市場 · 2024進行中
投資中
21 件のシグナル投資中 ステージ
3
🇨🇭スイス3rd 番目に参入した市場 · 2025進行中
投資中
11 件のシグナル投資中 ステージ
+8さらに市場ロック中
11件中3件を表示
現在のステージ投資中リソースを投入中
信頼度35%
追跡開始2022最初のシグナル

最近のシグナル

採用🇮🇹 イタリア2週間前

Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO

採用🇨🇭 スイス先月

Director, Medical Affairs

登録してシグナルフィードをすべて表示

知っておきたい情報

Alnylam Pharmaceuticals に関するよくある質問

Alnylam Pharmaceuticals の事業、市場、成長シグナルに関する簡潔な回答。

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

今日から旅を始めましょう

まずはプラットフォームでも、まずは会話からでも

Pubrio を自分で使うことも、リサーチ・リード獲得・データ連携を私たちに任せることもできます。

チームに相談
Start Journey Image
pubrio

Pubrio は 50 以上のローカルソースからビジネス・人物・インテントデータを統合し、AI と収益チームに市場全体の可視性を提供します。

© 2026 Pubrio. 無断転載を禁じます。